top of page

Viyash Scientific completes acquisition of BioForLife Italia

Oct 28
2 min read

The Indian pharmaceutical group has acquired the Milan based companion animal health company through its subsidiary Alivira Animal Health. The consideration includes EUR 15 million at closing and about EUR 1.976 million deferred.


Representative AI generated editorial illustration. It does not depict the actual company, facility, product or store.


Viyash Scientific has completed the acquisition of 100 per cent of BioForLife Italia, a Milan based company active in companion animal health products. The transaction was carried out through Alivira Animal Health, an Irish step down subsidiary of the Indian group, after the required approvals were received.


The acquisition closed on 1 October under the sale and purchase agreement signed in July. Viyash disclosed EUR 15 million payable at closing, together with approximately EUR 1.976 million of deferred consideration. The final amount remains subject to the agreement's adjustments based on BioForLife's net financial position at closing.


BioForLife develops, markets and distributes veterinary products for companion animals in Italy. The acquisition gives Viyash and Alivira a local commercial platform in a major European animal health market, including relationships with veterinary professionals and access to a portfolio focused on pets. Representatives of Alivira were appointed to BioForLife's board as part of closing.


The strategic value lies in distribution as much as ownership. An established Italian platform can help the Indian group introduce selected products more directly, while BioForLife may gain access to Alivira's wider development, manufacturing and international portfolio. These opportunities depend on regulatory approvals for individual products and the fit between the two commercial ranges.


For Italian life sciences businesses, the transaction shows continued Indian interest in specialised European healthcare assets with local market access. For Indian pharmaceutical groups, companion animal health offers a route to diversify beyond human generics and production led business models. Customer relationships, product registration knowledge and local brand credibility can be difficult to build quickly without an acquisition.


The transaction is complete, but the disclosed consideration is not necessarily the final economic cost because of closing adjustments and the deferred component. The next indicators will be integration progress, portfolio launches, retention of BioForLife's commercial network and any measurable contribution to Viyash's European animal health sales.


Sources and Credits

4 Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
Guest
4 days ago

The acquisition of BioForLife Italia marks an interesting step for Viyash Scientific’s growth. I’m curious to see how their combined expertise develops—I've been using https://vrew.pro/what-is-vrew

Like

Lopez74
Nov 01
Rated 5 out of 5 stars.

Viyash Scientific's strategic move to acquire BioForLife Italia highlights the significant value of established local platforms, especially for gaining immediate access to veterinary professionals and a focused pet product portfolio. It's a clever way for Indian pharmaceutical groups to diversify beyond human generics, sidestepping the challenge of building brand credibility and customer relationships from scratch. This kind of acquisition can truly offer a slope unblocked path to market entry and growth in a complex European landscape.

Like

Guest
Oct 30

Not only will this strategic acquisition enhance production efficiency for specialized treatments, but it will also establish a far stronger distribution network across key international markets. Just as staying focused through tricky platform drops in Drift Boss leads to unbelievable high score runs, clear corporate vision guarantees lasting industry impact. Fantastic growth news for the global scientific community!

Like

Ceyonne Ray
Oct 28
Rated 5 out of 5 stars.

It's fascinating to see Viyash Scientific expanding its portfolio with BioForLife Italia. This acquisition might enhance biotech innovation, similar to how free games az foster creativity in the gaming industry. Both fields thrive on discovery!

Like
bottom of page